A Story of Resilience, Family, and Hope

Prostate cancer has long been a part of the family’s history. A father, an older brother, and a twin brother all faced and overcame the disease. In August 2018, severe hip pain signaled that it was time for testing. Given the family history, a PSA test was requested, followed by bone and CT scans, which revealed widespread tumors in the skeleton and lymph nodes. From a hospital bed, the most critical decision was made: seeking treatment at MD Anderson.

On September 11, 2018, chemotherapy with docetaxel began, along with androgen deprivation therapy (ADT) to block testosterone, which fuels prostate cancer. The initial response was promising, but PSA levels soon began to rise, indicating the cancer had become “castration-resistant,” meaning it could produce its own testosterone.

A clinical trial provided new hope, combining cabazitaxel chemotherapy with abiraterone acetate and prednisone. The results were highly effective. Genetic testing also identified the HOXB13 mutation, known to increase the risk of early-onset prostate cancer. This discovery allows future generations of the family to take proactive steps for prevention.

A cancer diagnosis deepened the commitment to raising awareness and funding research. Participation in MD Anderson’s Boot Walk to End Cancer® began in 2016, but after the diagnosis, the event took on even greater meaning. With the employer LyondellBasell serving as a presenting sponsor, the drive to contribute and raise funds for research grew even stronger. Each year, the goal remains to increase awareness and fundraising efforts to support advancements in cancer treatment.

Facing cancer changed perspectives on life, leading to a deeper appreciation for each day. Moving to a dream home by the San Bernard River became a way to embrace life’s moments. For others on a similar journey, the most important advice is to trust instincts, ask questions, and take advantage of support systems.